TNFSF10 and neoplasm: On the 33rd day of post-treatment, the tumor size in the combination group was inhibited by 65%, to a much greater extent than that of mice treated with the intratumor injection of AAV/TRAIL only (36%) or single intraperitoneal administration with cisplatin (21%) (Figure 5A).